ERB-196

ERB-196, also known as WAY-202196, is a synthetic nonsteroidal estrogen that acts as a highly selective agonist of the ERβ.^{[1][2][3][4][5][6]} It possesses 78-fold selectivity for the ERβ over the ERα.^[1] The drug was under development by Wyeth for the treatment of inflammation and sepsis starting in 2004 but development was discontinued by 2011.^[2][7]

ERB-196

Clinical data
Other names	WAY-202196
Identifiers
IUPAC name 3-(3-Fluoro-4-hydroxyphenyl)-7-hydroxynaphthalene-1-carbonitrile
CAS Number	550997-55-2
PubChem CID	6102691
DrugBank	DB06875
ChemSpider	4810213
UNII	470CL5L4AC
ChEMBL	ChEMBL192154
CompTox Dashboard (EPA)	DTXSID70422018
Chemical and physical data
Formula	C17H10FNO2
Molar mass	279.270 g·mol−1
3D model (JSmol)	Interactive image
SMILES C1(=CC2=C(C(=C1)C#N)C=C(C=C2)O)C1=CC(=C(C=C1)O)F
InChI InChI=1S/C17H10FNO2/c18-16-7-10(2-4-17(16)21)12-5-11-1-3-14(20)8-15(11)13(6-12)9-19/h1-8,20-21H Key:NSSOSHDCWCMNDM-UHFFFAOYSA-N

See also

• 8β-VE2
• Diarylpropionitrile
• FERb 033
• Prinaberel
• WAY-166818
• WAY-200070
• WAY-214156